

sub B1  
A1 1. (Amended) A method for effecting a change in the biochemistry or function of  
the central nervous system comprising parenteral administration of an effective amount of an  
IGF-I.

sub B3  
A2 8. (Amended) A method for effecting a change in the biochemistry or function of  
the central nervous system comprising parenteral administration of an effective amount of an  
IGF-II.

sub B4  
A3 --19. A method according to claim 1, wherein IGF-I is administered in an amount  
effective to treat a noradrenergic neuron in the central nervous system.

20. A method according to claim 8, wherein IGF-II is administered in an amount  
effective to treat a noradrenergic neuron in the central nervous system.--

## REMARKS

### I. Informal Drawings

The cover page of the outstanding Office Action states that formal drawings are required in response to this Office Action. Applicant will promptly submit formal drawings upon receipt of a Notice of Allowance for this application.

### II. Provisional Obviousness-type Double Patenting Rejection

Claims 1-2, 8-9 and 15-16 are provisionally rejected under the doctrine of obviousness-type double patenting as allegedly being unpatentable over claims 6-9, 14-17 and 22-24 of copending U.S. application serial no. 08/398,852.

Serial No. 08/571,802  
Response to Office Action Mailed March 20, 1997